Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Meribank Biotech Co's Pretax Margin % or its related term are showing as below:
ROCO:4724'
s Pretax Margin % Range Over the Past 10 Years
Min: -60.83 Med: -32.62 Max: -4.3
Current: -18.85
ROCO:4724's Pretax Margin % is ranked better than 64.29% of 941
companies
in the Biotechnology industry
Industry Median: -89.42
vs ROCO:4724: -18.85
Meribank Biotech Co (ROCO:4724) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Meribank Biotech Co Pretax Margin % Related Terms
Meribank Biotech Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4724 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Meribank Biotech Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Meribank Biotech Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Meribank Biotech Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meribank Biotech Co (ROCO:4724) has a Pretax Margin % of -29.90% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Meribank Biotech Co and its competitors. According to the industry distribution chart, Meribank Biotech Co ranks #336 out of 941 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Meribank Biotech Co's Pretax Margin % too high?
Meribank Biotech Co's current Pretax Margin % is -29.90%. Based on the distribution chart, Meribank Biotech Co ranks #336 out of 941 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Meribank Biotech Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Meribank Biotech Co ranks #336 out of 941 companies for Pretax Margin %. This puts Meribank Biotech Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Meribank Biotech Co and its competitors. Meribank Biotech Co's current Pretax Margin % is -29.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.90, compared to a current price of NT$9.78 — trading 80% below its estimated fair value. The current Pretax Margin % is -29.90%. Meribank Biotech Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Pretax Margin % is -29.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$9.78 is trading 80% below its estimated GF Value™ of NT$48.90.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
Pretax Margin %: -29.90%
GF Value™: NT$48.90 vs. price of NT$9.78 (80% below fair value)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
40GF Score
Get the complete analysis for ROCO:4724
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
